Company news

Neurotech International Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children

September 8, 2024

Neurotech Global Partnering and Registration Strategy

August 11, 2024

Further Significant Improvement in Rett Syndrome Patients

July 30, 2024

Phase II/III autism trial shows further benefits

July 17, 2024

Significant improvement in Autism patients at 12 weeks

July 9, 2024

Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment

June 16, 2024

Further clinical benefit at 52 weeks in PANDAS/PANS patients

June 5, 2024

Rett Syndrome Phase I/II trial shows significant benefits

May 5, 2024

Neurotech Completes $10 Million Capital Raise

April 17, 2024

Positive Top-Line Rett Syndrome Clinical Trial Results

April 17, 2024

Phase II/III ASD Trial Successfully Meets Primary Endpoint

April 17, 2024

Last Patient Completes Treatment in NTIASD2 Clinical Trial

April 9, 2024

Rett Syndrome Patients to Receive NTI164 for 52 Weeks

March 12, 2024

PANDAS/PANS Patients Show Continued Clinical Improvement

February 20, 2024

Neurotech Receives Additional HREC Approval in Autism

February 12, 2024

NTI Receives HREC Approval for Cerebral Palsy Trial

January 28, 2024

Phase II/III Autism Clinical Trial Completes Recruitment

December 18, 2023

HREC Approval to Extend Phase II/III ASD Trial to Adults

December 3, 2023

Neurotech Receives $3.17 Million R&D Tax Incentive Refund

November 14, 2023

Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint

October 5, 2023

Completion of Patient Recruitment in NTIRTT1 Clinical Trial

September 26, 2023

Last Patient Completes Treatment in NTIPANS1 Clinical Trial

August 30, 2023

Appendix 4E & Annual Report

August 30, 2023

First Patient Treated in Rett Syndrome Clinical Trial

August 1, 2023

NTI Receives HREC Approval for Rett Syndrome Clinical Trial

July 9, 2023

NTI Granted 2 Year Extension of Treatment for ASD Patients

May 30, 2023

NTI granted HREC Approval for PANDAS/PANS Trial Extension

May 29, 2023

NTI Completes Recruitment in PANDAS/PANS Clinical Trial

May 2, 2023

NTI to Launch Phase II Clinical Trial in Rett Syndrome

March 19, 2023

Phase I/II ASD Clinical Trials Results at 52 Weeks

March 16, 2023

First Patient Treated in Phase I/II PANDAS/PANS Trial

February 16, 2023

Approval for Additional Phase I/II ASD Trial Extension

February 13, 2023

HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

January 26, 2023

NTI Granted FDA Pre-IND Meeting for NTI164 in ASD

January 19, 2023

Disclosure Document

December 22, 2022

Commencement of Phase II/III ASD Clinical Trial

December 19, 2022

NTI Receives HREC/TGA Approval for Phase II/III ASD Trial

November 16, 2022

Neurotech Receives $1.2M R&D Tax Rebate

October 31, 2022

Reinstatement to Quotation

October 27, 2022

Neurotech Completes $9.0M Placement

October 27, 2022

Suspension From Official Quotation

October 26, 2022

20 Week Data Shows Significant Improvement For ASD Children

October 25, 2022

New Phase I/II Clinical Trial in Children with PANDAS/PANS

October 16, 2022

Executive Change

September 1, 2022

Q&A on NTI164 Breakthrough Clinical Trial Results in ASD

July 21, 2022

Reinstatement to Official Quotation

July 7, 2022

Breakthrough results with NTI164 in paediatric asd

July 7, 2022

Extension to Voluntary Suspension

July 7, 2022

Suspension from Official Quotation

July 6, 2022

Preclinical Success with Targeted Combination Therapies

June 9, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 34 decks. Every deck is listed under its year.